undamentalytics Newsletter

Wang Lai: insider trades

Officer at Beone Medicines Ltd. No open-market purchases and 18 sales not made under a pre-set plan, reported from June 9, 2021 to June 25, 2026.

What happened after Wang Lai’s sales?

After their sales, the shares moved −13.4% against the index over 12 months on average (a negative figure means selling was the right call); 79% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Wang Lai: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 18 +13.8% +16.1% 22% 6 2.28 0.072 No reliable evidence
Sales, 12 months after the report 14 −13.4% −18.5% 79% 5 −0.46 0.67 No reliable evidence
Sales, 12 months after the trade 14 −14.5% −22.3% 71% 5 −0.55 0.61 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Beone Medicines Ltd. ONC President, Global Head of R&D018June 9, 2021June 25, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
June 25, 2026June 23, 2026 ONC Sale $295,558 +22.9%not yetnot yet
June 18, 2026June 16, 2026 ONC Sale $310,241 +30.4%not yetnot yet
June 15, 2026June 11, 2026 ONC Sale $197,316 +31.1%not yetnot yet
June 10, 2026June 8, 2026 ONC Sale $368,243 +29.3%not yetnot yet
June 25, 2025June 23, 2025 ONC Sale $267,280 +21.3%−8.5%−15.9%
June 18, 2025June 16, 2025 ONC Sale $431,697 +23.3%−13.1%−25.0%
June 10, 2025June 6, 2025 ONC Sale $353,855 +18.2%−24.0%−19.6%
June 26, 2024June 24, 2024 ONC Sale $170,030 +40.9%+53.9%+45.8%
June 20, 2024June 17, 2024 ONC Sale $368,159 +24.7%+58.2%+44.7%
June 27, 2023June 26, 2023 ONC Sale $201,562 +8.9%−47.1%−46.9%
June 20, 2023June 20, 2023 ONC Sale $254,956 +2.7%−42.8%−45.3%
June 9, 2023June 7, 2023 ONC Sale $103,828 −6.2%−47.8%−57.3%
June 28, 2022June 27, 2022 ONC Sale $81,213 −10.1%−8.6%−9.1%
June 22, 2022June 17, 2022 ONC Sale $169,767 −7.2%−0.7%+19.6%
June 8, 2022June 6, 2022 ONC Sale $93,720 +11.6%+31.6%+56.8%
June 30, 2021June 28, 2021 ONC Sale $164,928 +3.8%−42.1%−44.2%
June 21, 2021June 18, 2021 ONC Sale $265,582 +14.0%−42.9%−48.4%
June 9, 2021June 7, 2021 ONC Sale $232,395 −10.8%−53.3%−58.6%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Wang Lai traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.